Moving beyond a heat-labile enterotoxin-based vaccine against enterotoxigenic Escherichia coli

Affiliations

¹ Naval Medical Research Center, Silver Spring, MD 20910, USA. Electronic address: mark.riddle@med.navy.mil.
² Naval Medical Research Center, Silver Spring, MD 20910, USA.

Comment

Mark S Riddle et al. Lancet Infect Dis. 2014 Mar.

. 2014 Mar;14(3):174-5.

doi: 10.1016/S1473-3099(13)70355-4. Epub 2013 Nov 29.

¹ Naval Medical Research Center, Silver Spring, MD 20910, USA. Electronic address: mark.riddle@med.navy.mil.
² Naval Medical Research Center, Silver Spring, MD 20910, USA.

No abstract available

Comment on

Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.
Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, Jiang ZD, DuPont HL. Behrens RH, et al. Lancet Infect Dis. 2014 Mar;14(3):197-204. doi: 10.1016/S1473-3099(13)70297-4. Epub 2013 Nov 29. Lancet Infect Dis. 2014. PMID: 24291168 Clinical Trial.